Last reviewed · How we verify
Application of Enamel Matrix Derivatives
Enamel matrix derivatives promote periodontal tissue regeneration by mimicking the natural proteins present during tooth development and stimulating the migration and differentiation of periodontal ligament cells.
Enamel matrix derivatives promote periodontal tissue regeneration by mimicking the natural proteins present during tooth development and stimulating the migration and differentiation of periodontal ligament cells. Used for Periodontal defects and bone loss associated with periodontitis, Guided tissue regeneration in periodontal surgery.
At a glance
| Generic name | Application of Enamel Matrix Derivatives |
|---|---|
| Sponsor | Universidad Complutense de Madrid |
| Drug class | Regenerative biologic / Periodontal regenerative material |
| Target | Amelogenins and associated enamel matrix proteins |
| Modality | Biologic |
| Therapeutic area | Dentistry / Periodontics |
| Phase | FDA-approved |
Mechanism of action
Enamel matrix derivatives (EMD) are extracted from developing tooth buds and contain amelogenins and other proteins that guide tissue regeneration. When applied to periodontal defects, these proteins facilitate the recruitment and proliferation of undifferentiated mesenchymal cells, promoting the formation of new cementum, periodontal ligament, and alveolar bone. This biological approach recapitulates the natural healing cascade that occurs during tooth development.
Approved indications
- Periodontal defects and bone loss associated with periodontitis
- Guided tissue regeneration in periodontal surgery
Common side effects
- Local inflammation or swelling at application site
- Temporary discomfort or sensitivity
- Allergic reaction (rare)
Key clinical trials
- Periodontal Regeneration at the Distal Site of Second Molars After the Extraction of Lower Included Third Molars (PHASE4)
- Evaluation of Clinical and Radiological Outcomes Following the Treatment of Periodontal Intraosseous Defects Using Autogenous Tooth-derived Graft or Autogenous Bone Graft With Enamel Matrix Derivatives. A 12-month Randomized Controlled Clinical Trial. (NA)
- Rh-PDGF vs EMD for Treatment of Intra-bony Defects (PHASE1, PHASE2)
- Emdogain Adjunctive to Autotransplantation (PHASE4)
- Autotransplantation and Enamel Matrix Derivatives Case Series (NA)
- The Flapless Approach in Periodontal Regeneration (NA)
- Periodontal Regeneration With Hyaluronic Acid or Enamel Matrix Derivatives (NA)
- Entire Papilla Preservation Technique With and Without Biomaterials in the Treatment of Isolated Intrabony Defects (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: